Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

RNA Editing Market

ID: MRFR/HC/20494-HCR
128 Pages
Nidhi Mandole
Last Updated: April 24, 2026

RNA Editing Market Research Report Information By Type of RNA (Messenger RNA Modification, Transfer RNA Modification, Ribosomal RNA Modification), By Application (Cancer, Genetic Disorders And Temporary Maladies), By Technique (Insertion/ Deletion And Deamination), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

RNA Editing Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Type of RNA (USD Billion)
  49.     4.1.1 Messenger RNA Modification
  50.     4.1.2 Transfer RNA Modification
  51.     4.1.3 Ribosomal RNA Modification
  52.   4.2 Healthcare, BY Application (USD Billion)
  53.     4.2.1 Cancer
  54.     4.2.2 Genetic Disorders
  55.     4.2.3 Temporary Maladies
  56.   4.3 Healthcare, BY Technique (USD Billion)
  57.     4.3.1 Insertion/ Deletion
  58.     4.3.2 Deamination
  59.   4.4 Healthcare, BY Region (USD Billion)
  60.     4.4.1 North America
  61.       4.4.1.1 US
  62.       4.4.1.2 Canada
  63.     4.4.2 Europe
  64.       4.4.2.1 Germany
  65.       4.4.2.2 UK
  66.       4.4.2.3 France
  67.       4.4.2.4 Russia
  68.       4.4.2.5 Italy
  69.       4.4.2.6 Spain
  70.       4.4.2.7 Rest of Europe
  71.     4.4.3 APAC
  72.       4.4.3.1 China
  73.       4.4.3.2 India
  74.       4.4.3.3 Japan
  75.       4.4.3.4 South Korea
  76.       4.4.3.5 Malaysia
  77.       4.4.3.6 Thailand
  78.       4.4.3.7 Indonesia
  79.       4.4.3.8 Rest of APAC
  80.     4.4.4 South America
  81.       4.4.4.1 Brazil
  82.       4.4.4.2 Mexico
  83.       4.4.4.3 Argentina
  84.       4.4.4.4 Rest of South America
  85.     4.4.5 MEA
  86.       4.4.5.1 GCC Countries
  87.       4.4.5.2 South Africa
  88.       4.4.5.3 Rest of MEA
  89. 5 SECTION V: COMPETITIVE ANALYSIS
  90.   5.1 Competitive Landscape
  91.     5.1.1 Overview
  92.     5.1.2 Competitive Analysis
  93.     5.1.3 Market share Analysis
  94.     5.1.4 Major Growth Strategy in the Healthcare
  95.     5.1.5 Competitive Benchmarking
  96.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  97.     5.1.7 Key developments and growth strategies
  98.       5.1.7.1 New Product Launch/Service Deployment
  99.       5.1.7.2 Merger & Acquisitions
  100.       5.1.7.3 Joint Ventures
  101.     5.1.8 Major Players Financial Matrix
  102.       5.1.8.1 Sales and Operating Income
  103.       5.1.8.2 Major Players R&D Expenditure. 2023
  104.   5.2 Company Profiles
  105.     5.2.1 Editas Medicine (US)
  106.       5.2.1.1 Financial Overview
  107.       5.2.1.2 Products Offered
  108.       5.2.1.3 Key Developments
  109.       5.2.1.4 SWOT Analysis
  110.       5.2.1.5 Key Strategies
  111.     5.2.2 Intellia Therapeutics (US)
  112.       5.2.2.1 Financial Overview
  113.       5.2.2.2 Products Offered
  114.       5.2.2.3 Key Developments
  115.       5.2.2.4 SWOT Analysis
  116.       5.2.2.5 Key Strategies
  117.     5.2.3 CRISPR Therapeutics (CH)
  118.       5.2.3.1 Financial Overview
  119.       5.2.3.2 Products Offered
  120.       5.2.3.3 Key Developments
  121.       5.2.3.4 SWOT Analysis
  122.       5.2.3.5 Key Strategies
  123.     5.2.4 CureVac (DE)
  124.       5.2.4.1 Financial Overview
  125.       5.2.4.2 Products Offered
  126.       5.2.4.3 Key Developments
  127.       5.2.4.4 SWOT Analysis
  128.       5.2.4.5 Key Strategies
  129.     5.2.5 Avidity Biosciences (US)
  130.       5.2.5.1 Financial Overview
  131.       5.2.5.2 Products Offered
  132.       5.2.5.3 Key Developments
  133.       5.2.5.4 SWOT Analysis
  134.       5.2.5.5 Key Strategies
  135.     5.2.6 Beam Therapeutics (US)
  136.       5.2.6.1 Financial Overview
  137.       5.2.6.2 Products Offered
  138.       5.2.6.3 Key Developments
  139.       5.2.6.4 SWOT Analysis
  140.       5.2.6.5 Key Strategies
  141.     5.2.7 Alnylam Pharmaceuticals (US)
  142.       5.2.7.1 Financial Overview
  143.       5.2.7.2 Products Offered
  144.       5.2.7.3 Key Developments
  145.       5.2.7.4 SWOT Analysis
  146.       5.2.7.5 Key Strategies
  147.     5.2.8 Sangamo Therapeutics (US)
  148.       5.2.8.1 Financial Overview
  149.       5.2.8.2 Products Offered
  150.       5.2.8.3 Key Developments
  151.       5.2.8.4 SWOT Analysis
  152.       5.2.8.5 Key Strategies
  153.   5.3 Appendix
  154.     5.3.1 References
  155.     5.3.2 Related Reports
  156. 6 LIST OF FIGURES
  157.   6.1 MARKET SYNOPSIS
  158.   6.2 NORTH AMERICA MARKET ANALYSIS
  159.   6.3 US MARKET ANALYSIS BY TYPE OF RNA
  160.   6.4 US MARKET ANALYSIS BY APPLICATION
  161.   6.5 US MARKET ANALYSIS BY TECHNIQUE
  162.   6.6 CANADA MARKET ANALYSIS BY TYPE OF RNA
  163.   6.7 CANADA MARKET ANALYSIS BY APPLICATION
  164.   6.8 CANADA MARKET ANALYSIS BY TECHNIQUE
  165.   6.9 EUROPE MARKET ANALYSIS
  166.   6.10 GERMANY MARKET ANALYSIS BY TYPE OF RNA
  167.   6.11 GERMANY MARKET ANALYSIS BY APPLICATION
  168.   6.12 GERMANY MARKET ANALYSIS BY TECHNIQUE
  169.   6.13 UK MARKET ANALYSIS BY TYPE OF RNA
  170.   6.14 UK MARKET ANALYSIS BY APPLICATION
  171.   6.15 UK MARKET ANALYSIS BY TECHNIQUE
  172.   6.16 FRANCE MARKET ANALYSIS BY TYPE OF RNA
  173.   6.17 FRANCE MARKET ANALYSIS BY APPLICATION
  174.   6.18 FRANCE MARKET ANALYSIS BY TECHNIQUE
  175.   6.19 RUSSIA MARKET ANALYSIS BY TYPE OF RNA
  176.   6.20 RUSSIA MARKET ANALYSIS BY APPLICATION
  177.   6.21 RUSSIA MARKET ANALYSIS BY TECHNIQUE
  178.   6.22 ITALY MARKET ANALYSIS BY TYPE OF RNA
  179.   6.23 ITALY MARKET ANALYSIS BY APPLICATION
  180.   6.24 ITALY MARKET ANALYSIS BY TECHNIQUE
  181.   6.25 SPAIN MARKET ANALYSIS BY TYPE OF RNA
  182.   6.26 SPAIN MARKET ANALYSIS BY APPLICATION
  183.   6.27 SPAIN MARKET ANALYSIS BY TECHNIQUE
  184.   6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE OF RNA
  185.   6.29 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  186.   6.30 REST OF EUROPE MARKET ANALYSIS BY TECHNIQUE
  187.   6.31 APAC MARKET ANALYSIS
  188.   6.32 CHINA MARKET ANALYSIS BY TYPE OF RNA
  189.   6.33 CHINA MARKET ANALYSIS BY APPLICATION
  190.   6.34 CHINA MARKET ANALYSIS BY TECHNIQUE
  191.   6.35 INDIA MARKET ANALYSIS BY TYPE OF RNA
  192.   6.36 INDIA MARKET ANALYSIS BY APPLICATION
  193.   6.37 INDIA MARKET ANALYSIS BY TECHNIQUE
  194.   6.38 JAPAN MARKET ANALYSIS BY TYPE OF RNA
  195.   6.39 JAPAN MARKET ANALYSIS BY APPLICATION
  196.   6.40 JAPAN MARKET ANALYSIS BY TECHNIQUE
  197.   6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE OF RNA
  198.   6.42 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  199.   6.43 SOUTH KOREA MARKET ANALYSIS BY TECHNIQUE
  200.   6.44 MALAYSIA MARKET ANALYSIS BY TYPE OF RNA
  201.   6.45 MALAYSIA MARKET ANALYSIS BY APPLICATION
  202.   6.46 MALAYSIA MARKET ANALYSIS BY TECHNIQUE
  203.   6.47 THAILAND MARKET ANALYSIS BY TYPE OF RNA
  204.   6.48 THAILAND MARKET ANALYSIS BY APPLICATION
  205.   6.49 THAILAND MARKET ANALYSIS BY TECHNIQUE
  206.   6.50 INDONESIA MARKET ANALYSIS BY TYPE OF RNA
  207.   6.51 INDONESIA MARKET ANALYSIS BY APPLICATION
  208.   6.52 INDONESIA MARKET ANALYSIS BY TECHNIQUE
  209.   6.53 REST OF APAC MARKET ANALYSIS BY TYPE OF RNA
  210.   6.54 REST OF APAC MARKET ANALYSIS BY APPLICATION
  211.   6.55 REST OF APAC MARKET ANALYSIS BY TECHNIQUE
  212.   6.56 SOUTH AMERICA MARKET ANALYSIS
  213.   6.57 BRAZIL MARKET ANALYSIS BY TYPE OF RNA
  214.   6.58 BRAZIL MARKET ANALYSIS BY APPLICATION
  215.   6.59 BRAZIL MARKET ANALYSIS BY TECHNIQUE
  216.   6.60 MEXICO MARKET ANALYSIS BY TYPE OF RNA
  217.   6.61 MEXICO MARKET ANALYSIS BY APPLICATION
  218.   6.62 MEXICO MARKET ANALYSIS BY TECHNIQUE
  219.   6.63 ARGENTINA MARKET ANALYSIS BY TYPE OF RNA
  220.   6.64 ARGENTINA MARKET ANALYSIS BY APPLICATION
  221.   6.65 ARGENTINA MARKET ANALYSIS BY TECHNIQUE
  222.   6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF RNA
  223.   6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  224.   6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNIQUE
  225.   6.69 MEA MARKET ANALYSIS
  226.   6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF RNA
  227.   6.71 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  228.   6.72 GCC COUNTRIES MARKET ANALYSIS BY TECHNIQUE
  229.   6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF RNA
  230.   6.74 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  231.   6.75 SOUTH AFRICA MARKET ANALYSIS BY TECHNIQUE
  232.   6.76 REST OF MEA MARKET ANALYSIS BY TYPE OF RNA
  233.   6.77 REST OF MEA MARKET ANALYSIS BY APPLICATION
  234.   6.78 REST OF MEA MARKET ANALYSIS BY TECHNIQUE
  235.   6.79 KEY BUYING CRITERIA OF HEALTHCARE
  236.   6.80 RESEARCH PROCESS OF MRFR
  237.   6.81 DRO ANALYSIS OF HEALTHCARE
  238.   6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  239.   6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  240.   6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
  241.   6.85 HEALTHCARE, BY TYPE OF RNA, 2024 (% SHARE)
  242.   6.86 HEALTHCARE, BY TYPE OF RNA, 2024 TO 2035 (USD Billion)
  243.   6.87 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  244.   6.88 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  245.   6.89 HEALTHCARE, BY TECHNIQUE, 2024 (% SHARE)
  246.   6.90 HEALTHCARE, BY TECHNIQUE, 2024 TO 2035 (USD Billion)
  247.   6.91 BENCHMARKING OF MAJOR COMPETITORS
  248. 7 LIST OF TABLES
  249.   7.1 LIST OF ASSUMPTIONS
  250.     7.1.1
  251.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  252.     7.2.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  253.     7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  254.     7.2.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  255.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  256.     7.3.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  257.     7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
  258.     7.3.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  259.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  260.     7.4.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  261.     7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
  262.     7.4.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  263.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  264.     7.5.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  265.     7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
  266.     7.5.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  267.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  268.     7.6.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  269.     7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
  270.     7.6.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  271.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  272.     7.7.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  273.     7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
  274.     7.7.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  275.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  276.     7.8.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  277.     7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
  278.     7.8.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  279.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  280.     7.9.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  281.     7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
  282.     7.9.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  283.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  284.     7.10.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  285.     7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
  286.     7.10.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  287.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  288.     7.11.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  289.     7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
  290.     7.11.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  291.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  292.     7.12.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  293.     7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
  294.     7.12.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  295.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  296.     7.13.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  297.     7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
  298.     7.13.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  299.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  300.     7.14.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  301.     7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
  302.     7.14.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  303.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  304.     7.15.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  305.     7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
  306.     7.15.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  307.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  308.     7.16.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  309.     7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
  310.     7.16.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  311.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  312.     7.17.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  313.     7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
  314.     7.17.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  315.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  316.     7.18.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  317.     7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
  318.     7.18.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  319.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  320.     7.19.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  321.     7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
  322.     7.19.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  323.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  324.     7.20.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  325.     7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
  326.     7.20.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  327.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  328.     7.21.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  329.     7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
  330.     7.21.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  331.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  332.     7.22.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  333.     7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
  334.     7.22.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  335.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  336.     7.23.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  337.     7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
  338.     7.23.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  339.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  340.     7.24.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  341.     7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
  342.     7.24.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  343.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  344.     7.25.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  345.     7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
  346.     7.25.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  347.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  348.     7.26.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  349.     7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
  350.     7.26.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  351.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  352.     7.27.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  353.     7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
  354.     7.27.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  355.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  356.     7.28.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  357.     7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
  358.     7.28.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  359.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  360.     7.29.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  361.     7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
  362.     7.29.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  363.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  364.     7.30.1 BY TYPE OF RNA, 2025-2035 (USD Billion)
  365.     7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
  366.     7.30.3 BY TECHNIQUE, 2025-2035 (USD Billion)
  367.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  368.     7.31.1
  369.   7.32 ACQUISITION/PARTNERSHIP
  370.     7.32.1

Healthcare Market Segmentation

Healthcare By Type of RNA (USD Billion, 2025-2035)

  • Messenger RNA Modification
  • Transfer RNA Modification
  • Ribosomal RNA Modification

Healthcare By Application (USD Billion, 2025-2035)

  • Cancer
  • Genetic Disorders
  • Temporary Maladies

Healthcare By Technique (USD Billion, 2025-2035)

  • Insertion/ Deletion
  • Deamination

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions